Research and Markets has announced the addition of the "Raynauds Disease - Pipeline Review, H2 2016" report to their offering.
Raynauds Disease pipeline therapeutics constitutes close to 6 molecules, which approximately 6 molecules are developed by companies. Our latest report Raynauds Disease - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Raynauds Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Raynauds Disease Raynauds disease is a common condition that affects the blood supply to certain parts of the body, usually the fingers and toes. Predisposing factors include age, gender, family history and smoking. Symptoms include fingers, toes, ears, or nose to become white, and then turn blue. Treatment includes vasodilator, alpha blockers and calcium channel blockers. The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 2 respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Raynauds Disease and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/jr8p6h/raynauds_disease
View source version on businesswire.com: http://www.businesswire.com/news/home/20160928006101/en/Business Wire
Last updated on: 28/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.